Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation

Jeong Su Kim, Han Cheol Lee, Bo Kyung Choi, Hye Won Lee, Jin Sup Park, Yong Hwan Lee, Min Soo Ahn, Taek Jong Hong, Sang Pil Kim, Sang Kwon Lee, Yeong Dae Kim

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We investigated the impact of metabolic syndrome (MS) on the occurrence of in-stent restenosis (ISR) and long-term major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, and target vessel revascularization (TVR) during a follow-up period of 36 months after percutaneous coronary intervention (PCI) with stent implantation in patients with significant preexisting coronary artery disease. MS was not an independent predictor of increased ISR and MACE after PCI.

Original languageEnglish
Pages (from-to)e38-e41
JournalDiabetes Research and Clinical Practice
Volume88
Issue number3
DOIs
Publication statusPublished - 2010 Jun 1

Fingerprint

Stents
Percutaneous Coronary Intervention
Coronary Artery Disease
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kim, Jeong Su ; Lee, Han Cheol ; Choi, Bo Kyung ; Lee, Hye Won ; Park, Jin Sup ; Lee, Yong Hwan ; Ahn, Min Soo ; Hong, Taek Jong ; Kim, Sang Pil ; Lee, Sang Kwon ; Kim, Yeong Dae. / Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation. In: Diabetes Research and Clinical Practice. 2010 ; Vol. 88, No. 3. pp. e38-e41.
@article{71f24e0ca1b942e9bfea70239f435981,
title = "Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation",
abstract = "We investigated the impact of metabolic syndrome (MS) on the occurrence of in-stent restenosis (ISR) and long-term major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, and target vessel revascularization (TVR) during a follow-up period of 36 months after percutaneous coronary intervention (PCI) with stent implantation in patients with significant preexisting coronary artery disease. MS was not an independent predictor of increased ISR and MACE after PCI.",
author = "Kim, {Jeong Su} and Lee, {Han Cheol} and Choi, {Bo Kyung} and Lee, {Hye Won} and Park, {Jin Sup} and Lee, {Yong Hwan} and Ahn, {Min Soo} and Hong, {Taek Jong} and Kim, {Sang Pil} and Lee, {Sang Kwon} and Kim, {Yeong Dae}",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.diabres.2010.03.024",
language = "English",
volume = "88",
pages = "e38--e41",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation. / Kim, Jeong Su; Lee, Han Cheol; Choi, Bo Kyung; Lee, Hye Won; Park, Jin Sup; Lee, Yong Hwan; Ahn, Min Soo; Hong, Taek Jong; Kim, Sang Pil; Lee, Sang Kwon; Kim, Yeong Dae.

In: Diabetes Research and Clinical Practice, Vol. 88, No. 3, 01.06.2010, p. e38-e41.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation

AU - Kim, Jeong Su

AU - Lee, Han Cheol

AU - Choi, Bo Kyung

AU - Lee, Hye Won

AU - Park, Jin Sup

AU - Lee, Yong Hwan

AU - Ahn, Min Soo

AU - Hong, Taek Jong

AU - Kim, Sang Pil

AU - Lee, Sang Kwon

AU - Kim, Yeong Dae

PY - 2010/6/1

Y1 - 2010/6/1

N2 - We investigated the impact of metabolic syndrome (MS) on the occurrence of in-stent restenosis (ISR) and long-term major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, and target vessel revascularization (TVR) during a follow-up period of 36 months after percutaneous coronary intervention (PCI) with stent implantation in patients with significant preexisting coronary artery disease. MS was not an independent predictor of increased ISR and MACE after PCI.

AB - We investigated the impact of metabolic syndrome (MS) on the occurrence of in-stent restenosis (ISR) and long-term major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, and target vessel revascularization (TVR) during a follow-up period of 36 months after percutaneous coronary intervention (PCI) with stent implantation in patients with significant preexisting coronary artery disease. MS was not an independent predictor of increased ISR and MACE after PCI.

UR - http://www.scopus.com/inward/record.url?scp=78349242535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349242535&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2010.03.024

DO - 10.1016/j.diabres.2010.03.024

M3 - Article

C2 - 20427098

AN - SCOPUS:78349242535

VL - 88

SP - e38-e41

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -